ArticleCureus2026
Differentiating Autoimmune Hepatitis From Sulfasalazine Toxicity: The Value of Clinicopathologic Correlation.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sulfasalazine is one of the commonly used disease-modifying anti-rheumatic drugs (DMARDs) for many inflammatory and autoimmune illnesses. Sulfasalazine is generally safe with consistent monitoring, as it can rarely cause clinically significant drug‑induced liver injury (DILI). Diagnosing DILI can be challenging in patients with autoimmune diseases due to positive baseline autoantibodies that may mimic autoimmune hepatitis (AIH) or lupus‑associated hepatitis. This case highlights severe hepatocellular DILI temporally associated with sulfasalazine exposure in a patient with Sjögren's disease and systemic lupus erythematosus (SLE), where positive antinuclear antibody (ANA) could have misleadingly suggested an autoimmune liver disease. Clinical course, targeted serologies, imaging, and histology supported sulfasalazine‑induced liver toxicity rather than autoimmune or viral hepatitis. Early recognition and discontinuation of the drug were associated with rapid clinical and biochemical improvement in liver function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.